Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Aptahem's nomination committee for the AGM next year has held a meeting. The nomination committee consists of three members represententing the three largest owners as of 30 September this year that wish to appoint a representative to the committee as well as one appointed board member as convener.
Members of the nomination committee for the AGM 2023 consists of Ivar Nordqvist, chairman of the committee, Christian Pettersson, Tina Persson together with Bert Junno, chairman of the board at Aptahem.
The nomination committee is tasked with making proposals for the chairman of the meeting, election of board members and board fees, election for auditor and auditor's fee and, to the extent deemed necessary, changes to the instructions for the nomination committee.
Shareholders who wish to submit proposals to the nomination committee can do so in writing to valberedning@aptahem.comor to the following address:
Att: Valberedningen
Aptahem AB
Norra Vallgatan 58
211 22 Malmö
The nomination committee's proposal will be presented in the notice to the annual general meeting and on the company's website.
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.